{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:32:00Z","timestamp":1786422720683,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conventional drug-drug interaction checkers predominantly rely on a two-dimensional approach, including pharmacokinetic and pharmacodynamic mechanisms. Emerging recognition of the gut microbiome is often an overlooked parameter in drug interferences. This study introduces a novel three-pillar risk stratification scoring model, incorporating pharmacomicrobiomics, to help refine the interaction landscape between antibiotics and immunomodulators for safer and more precise patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-four antibiotic-immunomodulator drug pairs were analyzed across eight major drug classes. A standardized Risk Score was developed, assigning weighted values to Pharmacokinetic, PD and PM mechanisms based on pharmacological plausibility and clinical severity. This model\u2019s findings were compared against established clinical classifications (Lexicomp\u00ae) to identify blind spots in traditional risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The three-pillar model revealed 106 mechanistic interactions, representing a 65.5% increase in identified pathways compared to traditional two-dimensional models. The average mechanism per drug pair increased to 1.65. While standard databases categorized most pairings as moderate risk (Category C), our scoring system classified 51.5% (n = 33) as High-Risk (TRS \u22654). The PM pillar was pivotal in explaining metabolic interferences, such as antibiotic-induced dysbiosis, leading to either toxic surges in Tacrolimus levels or therapeutic failure of Mycophenolate mofetil due to disrupted enterohepatic recycling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrating pharmacomicrobiomics as the third pillar of drug interactions uncovers an invisible layer of clinical risk. Traditional tools significantly underestimate the burden of interactions by omitting simultaneous interferences and the role of the gut microbiome as a pre-systemic filter. While the scoring system presented here represents a novel proposal that requires future clinical validation, it provides a necessary framework for precise prescribing and enhancing patient safety in vulnerable multimorbid patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1878471","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:11Z","timestamp":1786422071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Trip score \u2013 A three-pillar risk stratification model proposal for antibiotic and immunomodulator coadministration"],"prefix":"10.3389","volume":"17","author":[{"given":"Hanna","family":"Sebesi","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology ME1, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of T\u00e2rgu Mure\u015f","place":["T\u00e2rgu Mures, Romania"]},{"name":"Preclinical Studies Laboratory, UMFST","place":["Targu Mures, Romania"]},{"name":"The Organizing Institution for Doctoral University Studies (IOSUD) - Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology","place":["T\u00e2rgu Mure\u0219, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"B\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology ME1, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of T\u00e2rgu Mure\u015f","place":["T\u00e2rgu Mures, Romania"]},{"name":"Preclinical Studies Laboratory, UMFST","place":["Targu Mures, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3-Istv\u00e1n","family":"B\u00e1ba","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of T\u00e2rgu Mure\u015f","place":["T\u00e2rgu Mures, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Microbiology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of T\u00e2rgu Mure\u015f","place":["T\u00e2rgu Mures, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"646.e1","DOI":"10.1016\/j.cmi.2016.04.015","article-title":"Impact of a short exposure to levofloxacin on faecal densities and relative abundance of total and quinolone-resistant enterobacteriaceae","volume":"22","author":"Bernard","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5005\/jp-journals-10071-23439","article-title":"Drug interactions between antimicrobial and immunosuppressive agents in solid organ transplant recipients","volume":"25","author":"Bhagat","year":"2021","journal-title":"Indian J. Crit. Care Med. Peer-Rev Off. Publ."},{"key":"B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/bcp.13750","article-title":"CYP3A4\u2010mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1\u2010mediated effects on bilirubin glucuronidation in humans","volume":"84","author":"Chattopadhyay","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"152342","DOI":"10.1016\/j.seminoncol.2025.152342","article-title":"The interest of therapeutic and pharmacological drug monitoring of methotrexate: a systematic review","volume":"52","author":"Chellal","year":"2025","journal-title":"Semin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.1038\/s41598-021-86321-z","article-title":"Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice","volume":"11","author":"Choi","year":"2021","journal-title":"Sci. Rep."},{"key":"B7","unstructured":"Cyclophosphamide - an overview | ScienceDirect topics\n          \n          \n          2003"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.rcsop.2025.100655","article-title":"Comparative evaluation of artificial intelligence platforms and drug interaction screening databases using real-world patient data","volume":"20","author":"Domi\u00e1n","year":"2025","journal-title":"Explor Res. Clin. Soc. Pharm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","article-title":"Cyclosporin clinical pharmacokinetics","volume":"24","author":"Fahr","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2125.1995.tb05797.x","article-title":"N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity","volume":"40","author":"Gill","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/cpt.70066","article-title":"Pharmacomicrobiomics","volume":"118","author":"Gronich","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1124\/dmd.118.084772","article-title":"Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites","volume":"47","author":"Guo","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40800-018-0073-4","article-title":"Nephrotoxicity of ciprofloxacin: five cases and a review of the literature","volume":"5","author":"Hajji","year":"2018","journal-title":"Drug Saf. - Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/20009666.2018.1466598","article-title":"A deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole","volume":"8","author":"Hamid","year":"2018","journal-title":"J. Community Hosp. Intern Med. Perspect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/cpt.3329","article-title":"Comprehensive evaluation of OATP- and BCRP-mediated drug\u2013drug interactions of methotrexate using physiologically-based pharmacokinetic modeling","volume":"116","author":"Hwang","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B16","volume-title":"E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs - Scientific Guideline","year":"2005"},{"key":"B17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/1753-0407.13053","article-title":"Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID\u201019 pandemic","volume":"12","author":"Infante","year":"2020","journal-title":"J. Diabetes"},{"key":"B18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12885-025-13920-8","article-title":"Influence of psoriasis on infection risk and survival outcomes in patients with head and neck cancer: a retrospective cohort study","volume":"25","author":"Jian","year":"2025","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"177176","DOI":"10.1016\/j.ejphar.2024.177176","article-title":"Impact of calcineurin inhibitors on gut microbiota: focus on tacrolimus with evidence from in vivo and clinical studies","volume":"987","author":"Kunasol","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01789.x","article-title":"Evidence of an interaction between nifedipine and nafcillin in humans","volume":"55","author":"Lang","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/17425255.2024.2332366","article-title":"Risk factors associated with high-dose methotrexate induced toxicities","volume":"20","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Metabolism & Toxicol."},{"key":"B22","unstructured":"Narrow therapeutic index drugs | DrugBank\n          \n          \n          2026"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/biomedicines11051456","article-title":"Pharmacokinetics of biopharmaceuticals: their critical role in molecular design","volume":"11","author":"Ogihara","year":"2023","journal-title":"Biomedicines"},{"key":"B24","article-title":"Tacrolimus","volume-title":"Statpearls","author":"Patel","year":"2026"},{"key":"B25","article-title":"The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study","author":"Peto","year":"2025"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3389\/fimmu.2019.02608","article-title":"Triggers of autoimmunity: the role of bacterial infections in the extracellular exposure of lupus nuclear autoantigens","volume":"10","author":"Qiu","year":"2019","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/cpt.3740","article-title":"Microbiome-informed dosing: exploring gut microbial communities impact on mycophenolate enterohepatic circulation and therapeutic target achievement","volume":"118","author":"Saqr","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/antibiotics11081138","article-title":"Incidence and determinants of Piperacillin\/tazobactam-associated hypokalemia: a retrospective study","volume":"11","author":"Seo","year":"2022","journal-title":"Antibiotics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1032873","DOI":"10.3389\/fmicb.2022.1032873","article-title":"Unraveling the effects of sulfamethoxazole on the composition of gut microbiota and immune responses in Stichopus variegatus","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","article-title":"Macrolide \u2013 induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin","volume":"50","author":"Westphal","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"789334","DOI":"10.3389\/fimmu.2021.789334","article-title":"Pharmacomicrobiology of methotrexate in rheumatoid arthritis: gut microbiome as predictor of therapeutic response","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1745-7254.2008.00908.x","article-title":"Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes","volume":"29","author":"Zhang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"102669","DOI":"10.1016\/j.mtbio.2025.102669","article-title":"Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy","volume":"36","author":"Zhao","year":"2025","journal-title":"Mater Today Bio"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1878471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:15Z","timestamp":1786422075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1878471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1878471"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1878471","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1878471"}}